| Literature DB >> 30907150 |
Rodney Luwor1, Andrew P Morokoff1,2, Stephanie Amiridis1,3, Giovanna D'Abaco4, Lucia Paradiso1, Stanley S Stylli1,2, Hong P T Nguyen1, Mark Tarleton5, Kelly A Young5, Terence J O'Brien3,6,7, Phillip J Robinson5,8, Megan Chircop5,8, Adam McCluskey5, Nigel C Jones3,6,7.
Abstract
Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma cell lines and patient-derived GSCs were treated with dynamin inhibitors, Dynole 34-2 and CyDyn 4-36. We studied about cell viability, and GSC neurosphere formation in vitro and orthotopic tumour growth in vivo. Dynamin inhibition reduced glioblastoma cell line viability and suppressed neurosphere formation and migration of GSCs. Tumour growth was reduced by CyDyn 4-36 treatment. Dynamin 2 inhibition therefore represents a novel approach for stem cell-directed Glioblastoma therapy.Entities:
Keywords: Cancer biology; Cancer stem cells; Dynamin; Glioblastoma; Invasion
Mesh：
Substances：
Year: 2019 PMID： 30907150 DOI： 10.1080/07357907.2019.1582060
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176